Deciphera Pharmaceuticals (DCPH)

Deciphera Pharmaceuticals (DCPH) Healthcare & Pipeline Overview

Deciphera Pharmaceuticals is a biopharmaceutical company specializing in developing innovative therapies to combat drug resistance in cancer treatments. Their lead drug, QINLOCK, targets gastrointestinal stromal tumors (GIST), positioning them as a key player in the oncology space with a focus on improving patient outcomes through targeted therapies.

What Is the Investment Thesis for DCPH?

Deciphera Pharmaceuticals presents a focused investment opportunity within the oncology space, driven by its lead drug QINLOCK and a pipeline of targeted therapies. QINLOCK's approval for fourth-line GIST provides a revenue stream, while the INTRIGUE Phase 3 study for second-line GIST represents a significant growth catalyst. The development of vimseltinib for TGCT and DCC-3116 for RAS/RAF mutant cancers further diversifies the company's portfolio. However, the company's negative profit margin of -119.3% indicates ongoing losses, requiring careful monitoring of expenses and revenue growth. Successful clinical trial outcomes and regulatory approvals are crucial for realizing the company's potential. As of 2026-05-10, the market capitalization stands at $2.21 billion.

Based on FMP financials and quantitative analysis

DCPH Key Highlights

• Market Cap of $2.21B reflects investor valuation of Deciphera's pipeline and approved therapies.
• Gross Margin of 97.7% indicates strong pricing power for QINLOCK.
• Profit Margin of -119.3% highlights ongoing losses due to R&D and commercialization expenses.
• Beta of 0.18 suggests lower volatility compared to the overall market.
• Lead drug candidate QINLOCK targets gastrointestinal stromal tumors (GIST), a niche oncology market with unmet needs.

Who Are DCPH's Competitors?

DCPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are DCPH's Key Strengths?

• Approved drug (QINLOCK) for GIST treatment.
• Pipeline of targeted therapies in development.
• Strong expertise in kinase inhibitor development.
• Experienced management team.

What Are DCPH's Weaknesses?

• Negative profit margin and ongoing losses.
• Reliance on a limited number of products.
• Competition from larger pharmaceutical companies.
• Dependence on successful clinical trial outcomes.

What Could Drive DCPH Stock Higher?

• Data readout from the INTRIGUE Phase 3 study of QINLOCK in second-line GIST.
• Clinical trial results for vimseltinib in tenosynovial giant cell tumor (TGCT).
• Initiation of clinical trials for DCC-3116 in RAS/RAF mutant cancers.
• Continued commercialization and market penetration of QINLOCK.
• Strategic partnerships and collaborations to expand pipeline and market reach.

What Are the Key Risks for DCPH?

• Negative return on equity (-56.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for pipeline assets.
• Regulatory setbacks and delays in drug approvals.
• Competition from new and existing cancer therapies.
• Dependence on the commercial success of QINLOCK.
• High research and development expenses.

What Are the Growth Opportunities for DCPH?

• Expansion of QINLOCK into Second-Line GIST: The ongoing INTRIGUE Phase 3 study evaluating QINLOCK for the treatment of second-line GIST represents a significant growth opportunity. Success in this trial could expand QINLOCK's market reach and increase revenue. The GIST market is estimated to reach billions of dollars, and securing a larger share of this market would be a substantial catalyst for Deciphera. Results from the INTRIGUE study are expected in the near term, making this an upcoming catalyst.
• Development of Vimseltinib for TGCT: Vimseltinib, a CSF1R inhibitor, is being developed for the treatment of tenosynovial giant cell tumor (TGCT). TGCT represents a significant unmet medical need, and a successful clinical development program for vimseltinib could lead to regulatory approval and commercialization. The TGCT market is estimated to be worth hundreds of millions of dollars, offering a substantial revenue opportunity for Deciphera. Clinical trials are ongoing, with potential data readouts in the next few years.
• Advancement of DCC-3116 for RAS/RAF Mutant Cancers: DCC-3116, a preclinical-stage asset, targets RAS/RAF mutant cancers. These cancers represent a large patient population with limited treatment options. Successful preclinical development and subsequent clinical trials could lead to a breakthrough therapy for these difficult-to-treat cancers. The RAS/RAF mutant cancer market is estimated to be a multi-billion dollar market, offering a significant long-term growth opportunity for Deciphera. Clinical trials are expected to begin in the coming years.
• Strategic Partnerships and Collaborations: Deciphera can pursue strategic partnerships and collaborations with other pharmaceutical companies to accelerate the development and commercialization of its pipeline assets. These partnerships can provide access to additional funding, expertise, and market reach. The pharmaceutical industry is characterized by collaborations, and Deciphera can leverage this trend to enhance its growth prospects. Ongoing discussions with potential partners represent a continuous opportunity.
• Geographic Expansion: Deciphera can expand its geographic reach by launching QINLOCK and other pipeline products in new markets. This expansion would require regulatory approvals and commercial infrastructure, but it could significantly increase revenue and market share. The global oncology market is growing, and Deciphera can capitalize on this trend by expanding its presence in key regions. Ongoing market assessments are being conducted to identify optimal expansion opportunities.

What Opportunities Does DCPH Have?

• Expansion of QINLOCK into new indications.
• Regulatory approval of pipeline assets.
• Strategic partnerships and collaborations.
• Geographic expansion into new markets.

What Threats Does DCPH Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from new therapies.
• Patent expirations.

What Are DCPH's Competitive Advantages?

• Proprietary drug candidates with patent protection.
• Specialized expertise in kinase inhibitor development.
• Established relationships with oncologists and cancer centers.
• Regulatory exclusivity for approved drugs like QINLOCK.

What Does DCPH Do?

Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to enhancing the lives of cancer patients. The company focuses on addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Their lead drug candidate, QINLOCK (ripretinib), is approved for the treatment of fourth-line gastrointestinal stromal tumors (GIST). Deciphera is also investigating QINLOCK in the INTRIGUE Phase 3 study for the treatment of second-line GIST. Beyond QINLOCK, Deciphera is developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R), targeting tenosynovial giant cell tumor (TGCT). Additionally, DCC-3116 is in the preclinical stage, aimed at treating RAS/RAF mutant cancers. Deciphera's strategy centers on creating innovative therapies that overcome drug resistance, thereby improving outcomes for patients with various types of cancer. The company operates internationally, marketing and developing its products to reach a global patient population.

What Products and Services Does DCPH Offer?

• Develops and commercializes innovative therapies for cancer treatment.
• Focuses on addressing drug resistance mechanisms in cancer cells.
• Markets QINLOCK (ripretinib) for the treatment of gastrointestinal stromal tumors (GIST).
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Develops kinase inhibitors to target specific cancer pathways.
• Seeks regulatory approvals for its products in the United States and internationally.
• Engages in research and development to discover new cancer therapies.

How Does DCPH Make Money?

• Develops proprietary drug candidates targeting specific cancer mechanisms.
• Conducts clinical trials to demonstrate the safety and efficacy of its drugs.
• Seeks regulatory approval from agencies like the FDA to market its drugs.
• Commercializes and sells its approved drugs to healthcare providers and patients.

What Industry Does DCPH Operate In?

Deciphera Pharmaceuticals operates within the competitive specialty and generic drug manufacturing industry, focusing specifically on oncology. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in personalized medicine. Companies like Deciphera are vying to develop innovative treatments that address drug resistance and improve patient outcomes. The competitive landscape includes both large pharmaceutical companies with established oncology portfolios and smaller biotech firms with novel approaches. Deciphera's focus on kinase inhibitors and targeted therapies positions it within a segment of the market that demands scientific expertise and regulatory navigation.

Who Are DCPH's Key Customers?

• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that administer cancer therapies.
• Patients diagnosed with gastrointestinal stromal tumors (GIST) and other cancers.
• Pharmacies that dispense prescription medications.

FY2026 estForward Outlook

Wall Street analysts project Deciphera Pharmaceuticals revenue of about $379.8M for fiscal 2026, with EPS near $-0.58. The estimate reflects 7 contributing analysts.

DCPH Valuation & Market Position

With a $2.21B market cap, Deciphera Pharmaceuticals sits in the mid-cap segment of the market. Relative to its peer group, DCPH's quantitative score of 61/100 is roughly in line with the peer average of 65/100.

ROE -56%Key Financial Metrics

Return on equity for Deciphera Pharmaceuticals stands at -56.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Deciphera Pharmaceuticals's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 7.38 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Deciphera Pharmaceuticals operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Steven L. Hoerter. DCPH has traded publicly since 2017.

DCPH Financials

DCPH Latest News

DCPH Analyst Consensus

DCPH MoonshotScore

What Investors Ask About Deciphera Pharmaceuticals (DCPH) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources